BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 19703758)

  • 1. Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.
    Humphries J; Gossage JA; Modarai B; Burnand KG; Sisson TH; Murdoch C; Smith A
    J Vasc Surg; 2009 Nov; 50(5):1127-34. PubMed ID: 19703758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution.
    Gossage JA; Humphries J; Modarai B; Burnand KG; Smith A
    J Vasc Surg; 2006 Nov; 44(5):1085-90. PubMed ID: 17098546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.
    Singh I; Burnand KG; Collins M; Luttun A; Collen D; Boelhouwer B; Smith A
    Circulation; 2003 Feb; 107(6):869-75. PubMed ID: 12591758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice.
    Siefert SA; Chabasse C; Mukhopadhyay S; Hoofnagle MH; Strickland DK; Sarkar R; Antalis TM
    J Thromb Haemost; 2014 Oct; 12(10):1706-16. PubMed ID: 25041188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
    Sood V; Luke CE; Deatrick KB; Baldwin J; Miller EM; Elfline M; Upchurch GR; Wakefield TW; Henke PK
    Thromb Haemost; 2010 Dec; 104(6):1174-83. PubMed ID: 20886179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
    Baldwin JF; Sood V; Elfline MA; Luke CE; Dewyer NA; Diaz JA; Myers DD; Wakefield T; Henke PK
    J Vasc Surg; 2012 Oct; 56(4):1089-97. PubMed ID: 22796119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
    Lundgren CH; Sawa H; Sobel BE; Fujii S
    Circulation; 1994 Oct; 90(4):1927-34. PubMed ID: 7923681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.
    Farris SD; Hu JH; Krishnan R; Emery I; Chu T; Du L; Kremen M; Dichek HL; Gold E; Ramsey SA; Dichek DA
    J Biol Chem; 2011 Jun; 286(25):22665-77. PubMed ID: 21536666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
    Gu JM; Johns A; Morser J; Dole WP; Greaves DR; Deng GG
    J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
    Cunningham O; Campion S; Perry VH; Murray C; Sidenius N; Docagne F; Cunningham C
    Glia; 2009 Dec; 57(16):1802-14. PubMed ID: 19459212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
    Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
    Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activation in venous leg ulcers.
    Herouy Y; Trefzer D; Hellstern MO; Stark GB; Vanscheidt W; Schöpf E; Norgauer J
    Br J Dermatol; 2000 Nov; 143(5):930-6. PubMed ID: 11069499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fibrinolytic system: A new target for treatment of depression with psychedelics.
    Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
    Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of uPA, tPA, and PAI-1 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation.
    Nosaka M; Ishida Y; Kuninaka Y; Kimura A; Kondo T
    Int J Legal Med; 2012 May; 126(3):421-5. PubMed ID: 22361951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
    Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
    Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
    Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
    Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.